Candriam Luxembourg S.C.A. purchased a new position in NewLink Genetics Corporation (NASDAQ:NLNK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 75,000 shares of the biotechnology company’s stock, valued at approximately $551,000.

A number of other large investors also recently modified their holdings of the company. Ameriprise Financial Inc. bought a new stake in shares of NewLink Genetics Corporation during the first quarter worth about $3,453,000. Teza Capital Management LLC acquired a new stake in NewLink Genetics Corporation during the first quarter valued at $312,000. UBS Asset Management Americas Inc. acquired a new stake in NewLink Genetics Corporation during the first quarter valued at $297,000. Bank of New York Mellon Corp boosted its stake in NewLink Genetics Corporation by 59.6% in the first quarter. Bank of New York Mellon Corp now owns 202,540 shares of the biotechnology company’s stock valued at $4,881,000 after buying an additional 75,610 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in NewLink Genetics Corporation during the first quarter valued at $620,000. 51.42% of the stock is currently owned by institutional investors and hedge funds.

Shares of NewLink Genetics Corporation (NLNK) opened at 6.59 on Wednesday. NewLink Genetics Corporation has a 1-year low of $5.90 and a 1-year high of $25.17. The firm’s 50-day moving average price is $7.24 and its 200 day moving average price is $13.53. The company’s market capitalization is $193.88 million.

NewLink Genetics Corporation (NASDAQ:NLNK) last released its quarterly earnings results on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.21. The firm had revenue of $10.37 million during the quarter, compared to analyst estimates of $2.65 million. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. Equities analysts predict that NewLink Genetics Corporation will post ($2.82) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/candriam-luxembourg-s-c-a-purchases-new-position-in-newlink-genetics-corporation-nlnk/1493328.html.

Several equities research analysts have weighed in on NLNK shares. Cantor Fitzgerald set a $32.00 target price on NewLink Genetics Corporation and gave the stock a “buy” rating in a research note on Thursday, May 4th. Robert W. Baird restated an “outperform” rating and set a $25.00 target price on shares of NewLink Genetics Corporation in a research note on Monday, June 5th. ValuEngine upgraded NewLink Genetics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, May 19th. Zacks Investment Research cut NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, July 12th. Finally, Jefferies Group LLC restated a “hold” rating and set a $18.00 target price on shares of NewLink Genetics Corporation in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company. NewLink Genetics Corporation has a consensus rating of “Hold” and a consensus price target of $18.17.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corporation (NASDAQ:NLNK).

Institutional Ownership by Quarter for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.